Table 4.

HR, with 95% CI and p values, for the effect of RA, AS, PSA, SLE and SSc on all-cause mortality of male and female patients for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

Systemic rheumatic disease	Gender	0–36 months of follow-up			>36 months of follow-up
		HR (main effect)			HR (main effect)
			95% CI	P value		95% CI	P value
RA	Male	0.6	0.55 to 0.65	<0.001	1.13*	0.98 to 1.30	0.094
	Female	0.65	0.61 to 0.69	<0.001	1.13*	1.03 to 1.23	0.008
AS	Male	0.61	0.47 to 0.80	<0.001	1.06**	0.77 to 1.46	0.715
	Female	0.7	0.50 to 0.98	0.042	0.7	0.50 to 0.98	0.042
PsA	Male	0.68	0.57 to 0.81	<0.001	0.94**	0.72 to 1.22	0.63
	Female	0.69	0.55 to 0.84	<0.001	1.22*	0.93 to 1.60	0.147
SLE	Male	1.91	1.56 to 2.35	<0.001	1.91	1.56 to 2.35	<0.001
	Female	1.47	1.29 to 1.67	<0.001	1.87**	1.55 to 2.26	<0.001
SSc	Male	2.56	1.57 to 4.16	<0.001	7.28**	3.30 to 16.06	<0.001
	Female	2.23	1.83 to 2.72	<0.001	3.90**	2.87 to 5.29	<0.001

P value for interaction *<0.001; **<0.05.

AS, Ankylosing Spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.